title: Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.
abstract: Somatostatin analogs currently used in the treatment of acromegaly and other neuroendocrine tumors inhibit hormone secretion and cell proliferation by binding to somatostatin receptor type (SST) 2 and 5. The antiproliferative pathways coupled to these receptors have been only partially characterized. The aim of this study was to evaluate the effect of octreotide and super selective SST2 (BIM23120) and SST5 (BIM23206) analogs on apoptotic activity and apoptotic gene expression in human somatotroph tumor cells. Eight somatotroph tumors expressing similar levels of SST2 and SST5 evaluated by real-time PCR and western blot analyses were included in the study. In cultured cells obtained from these tumors, octreotide induced a dose-dependent increase of caspase-3 activity (160+/-20% vs basal at 10 nM) and cleaved cytokeratin 18 levels (172+/-25% vs basal) at concentrations higher than 0.1 nM. This effect was due to SST2 activation since BIM23120 elicited comparable responses, while BIM23206 was ineffective. BIM23120-stimulated apoptosis was dependent on phosphatases, since it was abrogated by the inhibitor orthovanadate, and independent from the induction of apoptosis-related genes, such as p53, p63, p73, Bcl-2, Bax, BID, BIK, TNFSF8, and FADD. In somatotroph tumors, both BIM23120 and BIM2306 caused growth arrest as indicated by the increase in p27 and decrease in cyclin D1 expression. In conclusion, the present study showed that octreotide-induced apoptosis in human somatotroph tumor cells by activating SST2. This effect, together with the cytostatic action exerted by both SST2 and SST5 analogs, might account for the tumor shrinkage observed in acromegalic patients treated with long-acting somatostatin analogs.
authors.affiliation: Institute of Endocrine Sciences, University of Milan, Fondazione IRCCS, Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena, Via Francesco Sforza 35, 20122 Milan, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Ferrante
authors.forename: C
authors.initials: C
authors.lastname: Pellegrini
authors.forename: S
authors.initials: S
authors.lastname: Bondioni
authors.forename: E
authors.initials: E
authors.lastname: Peverelli
authors.forename: M
authors.initials: M
authors.lastname: Locatelli
authors.forename: P
authors.initials: P
authors.lastname: Gelmini
authors.forename: P
authors.initials: P
authors.lastname: Luciani
authors.forename: A
authors.initials: A
authors.lastname: Peri
authors.forename: G
authors.initials: G
authors.lastname: Mantovani
authors.forename: S
authors.initials: S
authors.lastname: Bosari
authors.forename: P
authors.initials: P
authors.lastname: Beck-Peccoz
authors.forename: A
authors.initials: A
authors.lastname: Spada
authors.forename: A
authors.initials: A
authors.lastname: Lania
mesh_terms: D000172:Acromegaly; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D015282:Octreotide / Q000494:pharmacology*; D010911:Pituitary Neoplasms / Q000235:genetics / Q000473:pathology*; D012333:RNA, Messenger / Q000235:genetics; D017481:Receptors, Somatostatin / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D014407:Tumor Cells, Cultured
chemical_list: D012333:RNA, Messenger; D017481:Receptors, Somatostatin; C094573:somatostatin receptor 5; C093733:somatostatin receptor 2; D053148:Caspase 3; D015282:Octreotide